NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BeyondSpring Inc. (BYSI) Stock Analysis

BeyondSpring Inc. (BYSI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BYSI

$0.50

−$0.03 (−5.13%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BYSI with… →

BYSI Key Statistics

As of Oct 21, 2026
Trading
Open
$0.56
Previous Close
$0.52
Day's Range
0.47–0.56
52-Week Range
0.57–2.44
Volume
37.27K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.21
Valuation
Market Cap
$24.95M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.18
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$1.01M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
41.12M
1-Year Return
−77.46%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
855.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BYSI closed at $0.50, −77.46% over 1 year.

BeyondSpring Inc. (BYSI) has a market capitalization of $24.95M.

In fiscal 2025, BYSI reported revenue of $0.00.

BYSI Stock Return by Calendar Year

BeyondSpring Inc. (BYSI) return since Mar 2017: what $10,000 became

1 year
$10,000 $2,254
−77.46%
5 years
$10,000 $303
−96.97%
Since Mar 2017
$10,000 $295
−97.05%

If you had invested $10,000 in BeyondSpring Inc. (BYSI) at the close on March 9, 2017, the earliest close on record here, it would have been worth $295 at the close on October 21, 2026: −97.05% in total, −30.67% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.58%
2025+0.00%
2024+81.11%
2023−52.13%
2022−58.50%
2021−62.87%
2020−21.29%
2019−17.33%
2018−35.52%
2017 (partial year)+73.09%

As of October 21, 2026.

BYSI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.01M—
2024$0.00−$11.12M—
2023$0.00−$21.03M—
2022$1.35M−$33.28M−2,463.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$8.95M−$1.01M—
2024$0.00—−$8.75M−$11.12M—
2023$0.00—−$15.08M−$21.03M—
2022$1.35M—−$37.24M−$33.28M−2,463.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BeyondSpring Inc. (BYSI) at $24.95M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 44 employees.

The 52-week range on file runs from $0.57 to $2.44. The most recent close on file for BYSI is $0.50, dated October 21, 2026. That is −$0.03 (−5.13%) against the previous close.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $1.01M. Earnings per share on a trailing basis come to −0.18.

Across the 4 fiscal years on file, revenue moves from $1.35M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −77.46%. Across 5 years the annualized return works out at −50.31%. The reported beta is −0.21. Annualized volatility over the trailing 9 years is 113.91%.

Growth & Income

No dividend is on file for BYSI.

The strongest complete calendar year on file is 2024 at +81.11%; the weakest is 2021 at −62.87%. Of the 8 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −69.58%.

Peer Comparison

BeyondSpring Inc. (BYSI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BeyondSpring Inc. BYSI $24.95M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BeyondSpring Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Visit website →